

**MINUTES OF THE MEETING OF THE CUMBRIA AREA PRESCRIBING COMMITTEE  
HELD ON THURSDAY 15<sup>th</sup> DECEMBER 2016 AT 2.00PM  
ENTERPRISE HOUSE, KENDAL**

**Present:**

Lesley Angell	Senior Medicines Optimisation Pharmacist, NECS
Pauline Bourne	Senior Pharmacist, UHMBT
Andrea Loudon	Clinical Pharmacy Lead, CCG (Chair)
Dr Andrea Mulgrew	GP Prescribing Lead, Allerdale Locality
Sarah Roberts	Patient Voice representative
Dr Nirmalan Arulanantham	Clinical Pharmacologist General Physician, NCUHT
Helen Huck	Head of Pharmacy CPFT
Dr Julia Smith	GP Prescribing Lead, South Lakes Locality
Dr Amanda Pugh	GP Prescribing Lead, Furness Locality
Phillip Utting	Professional Secretary Cumbria APC & Senior Medicines Optimisation Technician, NECS

**In attendance**

Siobhan Brewer	Pharmacist, CPFT
Andrea Scott	Medicine Management Pharmacist, UHMBT

---

**APOLOGIES FOR ABSENCE**

*Action*

Ben Merriman	LPC Representative
Bill Glendinning	Chief Pharmacist, NCUHT

---

**DECLARATION OF INTERESTS**

All forms now received.

---

**MINUTES OF THE PREVIOUS MEETING**

The minutes of the previous meeting held on 13<sup>th</sup> October 2016 were approved with the following alteration:

94/16

**Prednisolone 10mg/ml oral solution and prednisolone 5mg tablets** For steroid responsive inflammatory conditions in children.

This product will replace prednisolone soluble tablets, the new product is more palatable and cost efficient. Plain 5mg tablets can also be used in older patients.- Noted – current RAG status maintained

**Prednisolone 1mg/ml oral solution and prednisolone 5mg tablets** Joint first choice preparation for the acute wheeze in children.

This product will replace prednisolone soluble tablets, the new product is more palatable and cost efficient. Plain 5mg tablets can also be used in older patients.— Noted - current RAG status maintained

---

**ACTION LOG FROM PREVIOUS MEETING (13<sup>th</sup> October 2016)**

Updates were given as follows:

72/15 – This action was completed  
03/16 – This action was completed  
56/16 – This action was completed  
84/16 – This action was completed  
95/16 – This action was completed  
97/16 – This action was completed  
102/16 – This action was completed  
103/16 – This action was completed  
104/16 – This action was completed  
105/16 – This action was completed  
106/16 – This action was completed  
113/16 – This action was completed  
115/16 – This action was completed

**126/15 – Azathioprine & Mercaptopurine SCG** – LA to review the SCG taking comments from Mr Dennis Burke and Dr Shadad (both NCUHT) into account. LA awaiting reply from Dr Chris McDonald - ONGOING

LA

**08/16 Transfer of care audit** – Report of the audit results was reviewed.

Actions from results still to be completed:

- I. Secondary care medication discharge form to be reviewed - this was reviewed but cannot be changed due to its electronic nature. - COMPLETED
- II. Report to be taken to the Local Professional Network for Pharmacy. - COMPLETED
- III. Report for Prescription Pad - ONGOING
- IV. Report to be uploaded to website - ONGOING

LA

**46/16(2) NICE Technology appraisals- TA388 Sacubitril valsartan** – Suggested changes:

Full NICE criteria to be added to first box.

Include requirement for GPs to prescribe once secondary care reviewed and stable

NA to feedback changes to author, final document to be circulated before the next meeting for comments. ONGOING

NA

**64/16 LMMG Psoriasis Biologics Agents consultation** – Cumbria APC approves the LMMG pathway which Cumbrian clinicians may wish to follow. BLUETEQ forms to be updated for initiation and continuation – ONGOING

LA

**68/16 Specials Guide –updated version (was Off-label uses of tablets and capsules) –**

Guidance circulated to members, comments to be returned to Phil Utting by the 20<sup>th</sup> January 2017, final version to be brought to the next meeting.

ALL

**77/16 Formulary amendments:**

July 2016

Noted

Minor Ailments Formulary review, BM to feedback to LPC. – ONGOING

BM

---

**101/16 COPD Treatment Algorithm** –The algorithm was APPROVED for use with the following alterations:

- I. Re-name” COPD Inhaler decision tool”
- II. Important point 1. to read “ Choose a device that the patient can use effectively”
- III. Can the abbreviation “CAT” have an explanation.
- IV. Trust Logos and approval / review dates to be added.

BG

The committee accepted the requirement to prescribe by brand name.  
Changes to be made and then document can be issued. COMPLETED.

---

**116/16 Recent LJF Formulary decisions and amendments – October 2016**

**Sacubitril valsartan Entresto®** - Treatment in adults with significant left ventricular systolic dysfunction. Noted – remains AMBER in line with NICE TA 388

**Secukinumab 150mg pre-filled syringe, 150mg pre-filled pen Cosentyx ®**- Treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy. Noted – remains RED in line with NICE TA 407

**Fulvestrant 250mg solution for injection Faslodex®** - Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on therapy with an anti-oestrogen. Noted – remains BLACK in line with TA239

**Nivolumab 40mg/4ml and 100mg/10ml vials of concentrate for solution for infusion Opdivo®** - Treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. Noted – RED

**Blinatumomab 38.5 micrograms powder for concentrate and solution for solution for infusion Blincyto®** The treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Noted – RED

**Crizotinib 200mg and 250mg hard capsule Xalkori®**- First line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Noted - RED

**Insulin Degludec 100units/ml solution for injection in pre-filled pen or cartridge and 200 units/ml solution for injection in pre-filled pen Tresiba®** - Treatment of diabetes mellitus in adults – Noted – RED in line with NG17. BLACK for children 1yr+.

**Nivolumab 10mg/ml concentrate for solution for infusion Opdivo®** - As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. – Noted remains RED in line with NICE TA384

**Zoledronic acid Zerlinda®** - Off-label use of zoledronic acid for the adjuvant use in women at high risk of recurrence to reduce the rate of breast cancer recurrence in bone. – Noted – RED

**Paliperidone 175mg, 263mg, 350mg, 525mg prolonged release suspension for injection. Trevicta®** - Three monthly injection, indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product. – Noted – RED

---

---

**Calcipotriol + betamethasone 50 micrograms/g and 0.5g/g cutaneous foam Enstilar®** -  
Topical treatment of psoriasis vulgaris in adults. – Noted GREEN

**Fosfomycin trometamol Granules for oral solution (equivalent to 3g fosfomycin)**  
**Monuril®** - Treatment of acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females.  
Prophylaxis in diagnostic and surgical transurethral procedures. – Noted remains AMBER in line with previous decision.

**Rilpivirine / emtricitabine / tenofovir alafenamide 200mg/25mg/25mg film coated tablets Odefsey®** - Treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg), infected with HIV-1 without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV-1 RNA<100,000 copies/ml. – Noted – RED NHS England

**Vitamin A Oral solution 10,000 units/ml** - Treatment of low vitamin A levels in children. This product would replace vitamin A 150,000 units/ml preparation which has been discontinued. - Noted GREEN

**Carfilzomib Kyprolis®** - In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Not recommended - noted. NHSE commissioned. GREY until NICE TA published

**Iron isomaltoside 1000 Diafer®** - Treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral preparations are ineffective or cannot be used. Not recommended - Noted – BLACK

**Bevacizumab Avastin®** - In combination with erlotinib for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Not recommended - noted. NHSE commissioned. GREY until NICE TA published

**Cobimetinib Cotellic®** - In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Not recommended - Noted – Considered under section 118/16

**Liraglutide Victoza®** - Monotherapy for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications. Not recommended - Noted – GREEN in line with NICE NG28.

**Budesonide / formoterol Symbicort Turbohaler® and Sumbicort®** - Treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) 50% to 70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy. Not recommended - Noted – BLACK

**Golimumab Simponi®** - In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40kg, who have responded inadequately to previous therapy with methotrexate. Not recommended - Noted – NHSE commissioned. GREY until NICE TA published

---

---

**Perampanel Fycompa®** - Adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. Not recommended - Noted BLACK

**Tocilizumab RoActemra®** - Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Not recommended - Noted – RED in line with TA247

**Ibrutinib Imbruvica®** - Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) Not recommended - Noted - NHSE commissioned. GREY until NICE TA published

**Ibrutinib Imbruvica®** - Treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. Not recommended -Noted - NHSE commissioned. GREY until NICE TA published

**Secukinumab Cosentyx®** - Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Not recommended - Noted - NHSE commissioned. GREY until NICE TA published

**Alirocumab Praluent®** - Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Not recommended- Noted – Remains RED in line with NICE TA 393

**Levofloxacin Quinsair®** - The management of chronic pulmonary infections due to *Pseudomonas aeruginosa* in adult patients with cystic fibrosis. Not recommended - Noted – NHSE commissioned

**Trametinib Mekinsit®** - In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Not recommended -Noted – remains RED in line with NICE TA 396

**Dasatinib Sprycel®** - For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. Not recommended -Noted –RAG status remains BLACK in line with NICE TA251.

**Idarucizumab Praxbind®** - Idarucizumab is a specific reversal agent for dabigatran and is indicated in adult patients treated with dabigatran etexilate when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding. Not recommended -Noted – RED

## November 2016

**Dexamethasone 700 micrograms intravitreal implant in applicator Ozurdex®** - Treatment of adult patients with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy. Recommended – Noted remains RED in line with NICE

---

**Levofloxacin 240mg nebuliser solution Quinsair®** - Management of chronic pulmonary infections due to *Pseudomonas aeruginosa* in adult patients with cystic fibrosis. Recommended- Noted – – NHSE commissioned

**Brivaracetam 10mg, 25mg, 75mg, 100mg film coated tablets; 10mg/ml oral solution; 10mg/ml solution for injection / infusion Briviact®** - Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. Recommended- Noted – AMBER – Injection RED

**Ibrutinib 140mg hard capsules Imbruvica®** - Treatment of adults with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. Recommended- Noted RAG status remains GREY until NICE TA published

**Ibrutinib 140mg hard capsules Imbruvica®** - Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Recommended -Noted RAG status remains GREY until NICE TA published

**Lenvatinib 4mg and 10mg hard capsules Lenvima®** - Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). Recommended - Noted – GREY until NICE TA published

**Secukinumab 150mg solution for injection in pre-filled pen and pre-filled syringe Cosentyx®** - Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Recommended– Noted – NHSE commissioned. GREY until NICE TA published

**Pegaspargase 750U/ml solution for injection/infusion Oncaspar®** - As a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients. Recommended -Noted – remains RED in line with NICE TA 408

**Ulipristal acetate 5mg tablet Esmya®** - Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. Not recommended- Noted – RAG status remains AMBER in line with previous decision.

**Apremilast 10mg, 20mg and 30mg film coated tablets Otezla®** - Treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA) – Not recommended. Considered under section 118/16

**Nexobrid®** Removal of eschar in adults with deep partial and full thickness thermal burns up to a maximum of 15% total body surface area. Not recommended – Noted BLACK

**Adalimumab Humira®** - Treatment of moderately active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or

---

immunomodulator, or who are intolerant to or have contraindications for such therapies. – Not recommended. Noted – NHSE commissioned-remains RED

**Adalimumab Humira®** - Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. – Not recommended - Noted – GREY until NICE TA published

**Canakinumab Ilaris®** - Treatment of active Still's disease including Adult-Onset Still's Disease who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate – Not recommended. Noted – GREY until NICE TA published

**Fampridine Fampyra®** - Improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4 to 7). Not recommended – Noted –remains BLACK in line with NICE CG186

**Lenalidomide Revlimid®** - Treatment of adults with relapsed or refractory mantle cell lymphoma.- Not recommended – Noted- GREY until NICE TA published

**Nivolumab Opdivo®** - Treatment of advanced renal cell carcinoma after prior therapy in adults. - Not recommended – Noted- Considered under section 118/16

**Aflibercept Eyelea®** - For adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV). Not recommended -Noted -- GREY until NICE TA published

**Budesonide Cortiment®** - In adults for induction of remission in patients with mild to moderate active ulcerative colitis (UC) where aminosalicylate (5-ASA) treatment is not sufficient. Noted – GREY until NICE TA published

**Dasatinib Sprycel®** - For the treatment of adult patients with chronic, accelerated or blast phase chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate. Not recommended. Noted – remains RED in line with relevant NICE TA

**Nivolumab Opdivo®** - Treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. Not recommended- Noted – GREY until NICE TA published

**Progesterone Lutigest®** - Luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women. Not recommended. Noted - BLACK

117/16

**Formulary amendments:**

October 2016

Noted

To be added to Prescription Pad

LA

---

118/16 **NICE TECHNOLOGY APPRAISALS**

**TA413 Elbasvir - grazoprevir** – Treating chronic hepatitis C – Recommended-Noted - RED

**TA414 Cobimetinib in combination with vemafurenib** - Treating unresectable or

---

---

metastatic BRAF V600 mutation -positive melanoma – Not recommended -Noted - BLACK

**TA415 Certolizumab pegol** - Treating rheumatoid arthritis after inadequate response to a TNF- alpha inhibitor – Recommended -Noted – RED

**TA416 Osimertinib** – Treating locally advanced or metastatic EGFR T790M mutation – positive non-small cell lung cancer – Recommended - Noted - RED

**TA417 Nivolumab** – Previously treated advanced renal cell carcinoma – Recommended-Noted - RED

**TA418 Dapagliflozin** - In triple therapy for treating type 2 diabetes, recommended as an option only in combination with metformin and a sulphonylurea. Noted - GREEN – LA  
Cumbria Blood Glucose Algorithm to be updated

**TA419 Apremilast** – Treating moderate to severe plaque psoriasis - Recommended–Noted – RED – BLUETEQ form to be added LA

---

119/16 **NICE CLINICAL GUIDELINES**

**NG57:** Physical health of people in prison – No prescribing recommendations - Noted

**NG58:** Coexisting severe mental illness and substance misuse: community health and social care services. – No prescribing recommendations - Noted

**NG59:** Low back pain and sciatica in over 16s: assessment and management.  
- Noted, NA to feedback to NCUHT at the D&T meeting. NA  
To be added to prescription Pad – not to refer patients for Spinal injections. LA

**NG60:** HIV testing: increasing uptake among people who may have undiagnosed HIV (Joint NICE and PHE guideline) . – No prescribing recommendations – Noted

---

120/16 **NICE Medicines Optimisation NG5**

Nothing to discuss

---

121/16 **CONTRACT MONITORING**

NERSAP meeting notes (Sept 16) reviewed and noted.  
Spiolto rebate scheme approval noted. Cumbria APC accepts the NERSAP recommendation.

---

122/16 **MEDICINES SAFETY**

Siobhan Brewer presented a SIRI from CPFT regarding a patient death due to Lithium toxicity.

Recommendations from the SIRI panel at CPFT:

- I. CPFT will create a database of all patients currently prescribed Lithium under the care of CPFT.
- II. Create a shared care guideline for Lithium with a monitoring process included.

CPFT has issued guidance to it's prescribers on Lithium prescribing

---



	<p>Cumbria CCG has asked PRIMIS to create an audit for all patients prescribed Lithium, to include any interacting drugs. It will be possible for practices to run this monthly to ensure patients are monitored appropriately. Report to be brought to next meeting.</p> <p>CPFT to explore possibility of Cumbria wide database to include all patients prescribed lithium, to report to next meeting.</p> <p>Develop Shared Care Guidance</p> <p>To be added to prescription pad.</p>	<p>AL</p> <p>HH</p> <p>HH</p> <p>LA</p>
<b>CLINICAL MATTERS</b>		
123/16	<b>Guide to your Just in Case Medication</b> – Updated version circulated, Trust logos, date and review dates to be added before circulation. - APPROVED	HH
124/16	<p><b>Liothyronine RAG rating review</b> – The committee reviewed the RAG rating of Liothyronine following request from Dr Cathy Hay. The committee reconsidered the evidence for liothyronine and upheld the decision made in October 2015 to allocate a BLACK RAG rating. It was decided to include Armour Thyroid in this. The committee discussed the implementation of this RAG rating and agreed that (in line with NICE principles) that there should be no new prescribing but that patients who are already prescribed this drug may continue until they and their NHS clinician consider it appropriate to stop. All patients currently prescribed a drug allocated a BLACK RAG rating should be reviewed by the prescribing clinician with a view to managing their condition in line with the evidence and the APC decision. The shared decision made at this review should be regularly revisited. It may be appropriate for a GP to refer the patient to a specialist if they or the patient feel they need further advice to enable them to manage their condition. If, after specialist review, prescribing is to continue, the consultant can ask the GP to continue prescribing if the GP was prescribing previously.</p> <p>RAG list to be updated and add to Prescription Pad. – ONGOING</p>	
125/16	<p><b>RDTC reports</b> – Q1 Prescribing reports were circulated for information.</p> <ul style="list-style-type: none"> <li>• Oral nutrition – noted Cumbria prescribing is generally cost effective. Higher costs in infant formula is due to product choice of specialist products under specialist supervision.</li> <li>• Pain management – Above England average spend for non-opioid prescribing due to Nefopam. Hyaluronic acid prescribing – 2 practices to action.</li> </ul> <p>Noted for information.</p>	LA
126/16	<b>Sodium Aurothiomalate (GOLD) SCG</b> – Current LMMG guideline circulated. Handover to primary care to be made clearer in the document. Review in line with BSR updated monitoring recommendations. Changes to be made and be brought to next meeting. - ONGOING	PB
127/16	<b>Methotrexate SCG</b> – Updated document circulated to show the licensed indications and the “off-license” use in Crohn’s clearer. To be updated to show all products and strengths available and brought back to next meeting. - ONGOING	LA
128/16	<b>Diabetic foot infection guideline</b> – Guideline APPROVED – to be added to NECS MO website and add to Prescription Pad. - ONGOING	LA
129/16	<b>Alirocumab and Evolocumab LDL cholesterol reduction</b> – NHSE statement discussed. BLUETEQ forms to be updated to include continue only if a 30% reduction has been achieved at 12 weeks. - ONGOING	LA

130/16	<b>Hydroxycarbamide SCG</b> – There are currently two SCG's in operation, one for Haematology and one for Dermatology. The Haematology SCG has no changes so APPROVED, the Dermatology SCG is to be reviewed if it is still required, to be brought back to the next meeting. - ONGOING	PB
131/16	<b>Collaborative working on SCG's</b> – When SCG's are due for review, Cumbria will review against the LMMG guidelines. All trust logo's to remain on the current SCGs.- COMPLETED	
132/16	<b>Avastin &amp; Lucentis briefing note</b> – Noted for information however the legislation has not changed on this subject. -COMPLETED	
133/16	<b>NTAG – Alfapump device</b> – Noted for information (device) – recommended for refractory ascites caused by advanced liver disease as recommended by specialists for patients that fulfil the specified criteria. - COMPLETED	
134/16	<b>NTAG – Qutenza (capsaicin) cutaneous patch for neuropathic pain</b> – Noted – NOT RECOMMENDED for neuropathic pain – Cumbria usage to be brought to the next meeting.- ONGOING	LA
135/16	<b>Cinacalcet RAG rating review</b> – Request by NA to be changed to AMBER, paper to be brought to the next meeting – ONGOING	NA
136/16	<b>Q1 Antibiotic prescribing NCUHT &amp; UHMBT</b> - noted for information – COMPLETED	
137/16	<b>Denosumab prescribing guideline for primary care</b> – The following changes to be made to the document then circulated to the committee with comments back by the 20 <sup>th</sup> Jan 2017: I. Flow diagram to be added to the guideline. II. Remove red writing and the appendix. III. Remove paragraph 3 from the introduction section. Final version to be brought to the next meeting – ONGOING	LA
138/16	<b>Updated PPI Specials guideline</b> – The following change to be made: I. “patient” to be changed to “parent” APPROVED – to be added to NECS MO website and Prescription Pad.	LA
139/16	<b>OPERATIONAL</b>  Nothing to discuss	
<b>DRUG SAFETY UPDATE</b>		
140/16	Drug Safety Update (October 2016) – Noted, point 1 to be added to Prescription Pad.	LA
141/16	Drug Safety Update (November 2016) – Noted, point 2 add to Prescription Pad.	LA
142/16	<b>FOR INFORMATION</b>  <b>Minutes received:</b>  Lothian Formulary Committee (October 2016)	

---

Lothian Formulary Committee (November 2016)

NTAG meeting minutes – (November 2016)

Antimicrobial management team meeting – (October 2016)

---

**ANY OTHER BUSINESS**

- 143/16 NA asked if the February 2017 meeting could be moved to later in the month, this meeting has already been moved once and other members already have their calendars fixed.
- 144/16 The committee wished to record it thanks to Pauline Bourne for her work on the committee for many years and to wish her a long and happy retirement. Andrea Scott (present) will be taking over the role of Medicines Management in UHMBT and will be attending future meetings.
- 

**DATE and TIME of next meeting**

**Thursday 9<sup>th</sup> February 2017, 2pm at PRUFC, Penrith**

---